Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes

TP53 mutations are associated with adverse outcomes and shorter response to hypomethylating agents (HMAs) in myelodysplastic syndrome (MDS). Limited data have evaluated the impact of the type, number, and patterns of TP53 mutations in response outcomes and prognosis of MDS. We evaluated the clinicop...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Blood Adv
Autores principales: Montalban-Bravo, Guillermo, Kanagal-Shamanna, Rashmi, Benton, Christopher B., Class, Caleb A., Chien, Kelly S., Sasaki, Koji, Naqvi, Kiran, Alvarado, Yesid, Kadia, Tapan M., Ravandi, Farhad, Daver, Naval, Takahashi, Koichi, Jabbour, Elias, Borthakur, Gautham, Pemmaraju, Naveen, Konopleva, Marina, Soltysiak, Kelly A., Pierce, Sherry R., Bueso-Ramos, Carlos E., Patel, Keyur P., Kantarjian, Hagop, Garcia-Manero, Guillermo
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Hematology 2020
Materias:
Myeloid Neoplasia
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7013259/
https://ncbi.nlm.nih.gov/pubmed/32027746
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019001101
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares